The GUARD Trial - Part 1: A Phase 3 Clinical Trial for Prevention of Proliferative Vitreoretinopathy
Study sponsor: Aldeyra Therapeutics, Inc. · ALDX
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2022-06-14Actual
Enrollment · participants106Actual
Source updated2025-07-09Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.